US 11,771,692 B2
N-hydroxyethyl didehydroazapodophyllotoxins as GBP1 inhibitors and methods of overcoming treatment resistance in cancer
Sanjay Malhotra, Palo Alto, CA (US); Vineet Kumar, Palo Alto, CA (US); and Dhanir Tailor, Palo Alto, CA (US)
Assigned to The Board of Trustees of the Leland Stanford Junior University, Stanford, CA (US)
Appl. No. 16/971,639
Filed by The Board of Trustees of the Leland Stanford Junior University, Stanford, CA (US)
PCT Filed Mar. 12, 2019, PCT No. PCT/US2019/021840
§ 371(c)(1), (2) Date Aug. 20, 2020,
PCT Pub. No. WO2019/178091, PCT Pub. Date Sep. 19, 2019.
Claims priority of provisional application 62/642,383, filed on Mar. 13, 2018.
Prior Publication US 2020/0375977 A1, Dec. 3, 2020
Int. Cl. A61P 35/00 (2006.01); C07D 215/14 (2006.01); C07D 491/048 (2006.01); C07D 491/153 (2006.01); C07D 221/06 (2006.01); C07D 221/18 (2006.01); A61K 31/4741 (2006.01); A61K 31/337 (2006.01); A61K 31/473 (2006.01); A61K 45/06 (2006.01)
CPC A61K 31/4741 (2013.01) [A61K 31/337 (2013.01); A61K 31/473 (2013.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01); C07D 215/14 (2013.01); C07D 491/048 (2013.01); C07D 491/153 (2013.01)] 21 Claims
 
1. A compound, having the structure:

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt or a solvate thereof.